Jazz Pharmaceuticals Q3 2026 Results: Net Loss of $483M
Jazz Pharmaceuticals reported its financial results for the third quarter of 2026, highlighting the acquisition of Actio Biosciences and the approval of Modeyso. The company also amended its credit agreement to refinance its term loans and increase its revolving credit facility to $885 million.
- Key figure
- Net loss $483M